Brookside Capital, Deerfield Management Company, Rock Springs Capital, T Rowe Price Associates, Wellington Management Company and the company’s founder, the Children’s Hospital of Philadelphia, also participated in the round.
The company will use the funds to advance its pipeline of gene therapy programmes including its lead Phase 3 programme to address RPE65-related retinal dystrophies.
Spark has also recently unveiled plans to open its corporate headquarters and manufacturing facility.
Sofinnova general partner Anand Mehra said, “The Spark team has significant experience across the core capabilities required to develop gene therapy products as evidenced by the quality of the company’s pipeline and programs.
“The benefit provided by the RPE65 product candidate has the potential to be transformative for patients’ lives.”
Earlier this month Sofinnova led a €16.5m Series A financing for gene therapy biotechnology company Lysogene.
Copyright © 2014 AltAssets